PT2341142E - Péptido wt1 restringido a hla-a*1101 e composição farmacêutica compreendendo o mesmo - Google Patents

Péptido wt1 restringido a hla-a*1101 e composição farmacêutica compreendendo o mesmo Download PDF

Info

Publication number
PT2341142E
PT2341142E PT101912343T PT10191234T PT2341142E PT 2341142 E PT2341142 E PT 2341142E PT 101912343 T PT101912343 T PT 101912343T PT 10191234 T PT10191234 T PT 10191234T PT 2341142 E PT2341142 E PT 2341142E
Authority
PT
Portugal
Prior art keywords
hla
peptide
restricted
same
pharmaceutical composition
Prior art date
Application number
PT101912343T
Other languages
English (en)
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Publication of PT2341142E publication Critical patent/PT2341142E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
PT101912343T 2006-12-28 2007-12-14 Péptido wt1 restringido a hla-a*1101 e composição farmacêutica compreendendo o mesmo PT2341142E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006355356 2006-12-28

Publications (1)

Publication Number Publication Date
PT2341142E true PT2341142E (pt) 2015-02-13

Family

ID=39588385

Family Applications (1)

Application Number Title Priority Date Filing Date
PT101912343T PT2341142E (pt) 2006-12-28 2007-12-14 Péptido wt1 restringido a hla-a*1101 e composição farmacêutica compreendendo o mesmo

Country Status (28)

Country Link
US (4) US8653038B2 (pt)
EP (6) EP2479275B1 (pt)
JP (1) JP5484734B2 (pt)
KR (1) KR101525261B1 (pt)
CN (5) CN102295682A (pt)
AR (1) AR064555A1 (pt)
AU (1) AU2007340679B2 (pt)
BR (1) BRPI0720988A2 (pt)
CA (5) CA2886622A1 (pt)
CY (1) CY1116011T1 (pt)
DK (3) DK2479276T3 (pt)
ES (4) ES2554775T3 (pt)
HK (3) HK1159686A1 (pt)
IL (4) IL199052A0 (pt)
MX (1) MX2009007008A (pt)
MY (1) MY161664A (pt)
NO (1) NO20092774L (pt)
NZ (4) NZ601175A (pt)
PH (1) PH12014500902A1 (pt)
PL (1) PL2341142T3 (pt)
PT (1) PT2341142E (pt)
RU (1) RU2481398C2 (pt)
SG (1) SG177222A1 (pt)
SI (1) SI2341142T1 (pt)
TW (3) TWI417103B (pt)
UA (1) UA103154C2 (pt)
WO (1) WO2008081701A1 (pt)
ZA (1) ZA200903633B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2378264T3 (es) 2003-11-05 2012-04-10 International Institute Of Cancer Immunology, Inc. Péptido antigénico de unión a HLA-DR derivado de WT1
CA2900087C (en) 2005-10-17 2024-02-13 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
RU2680539C2 (ru) 2007-02-27 2019-02-22 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. Способ активации хелперных т-клеток и композиция для применения в данном способе
SG189287A1 (en) 2010-10-05 2013-05-31 Int Inst Cancer Immunology Inc Method for activating helper t cell
SG193956A1 (en) * 2011-04-01 2013-11-29 Sloan Kettering Inst Cancer T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
EP2757373A4 (en) * 2011-09-14 2015-07-01 Int Inst Cancer Immunology Inc METHOD FOR MEASURING ANTI-WT1 ANTIBODIES
WO2013106834A2 (en) 2012-01-13 2013-07-18 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
WO2014042226A1 (ja) 2012-09-12 2014-03-20 株式会社癌免疫研究所 抗原特異的ヘルパーｔ細胞レセプター遺伝子
KR102208505B1 (ko) 2012-12-11 2021-01-27 앨버트 아인슈타인 컬리지 오브 메디신 고처리량 수용체:리간드 확인을 위한 방법
TWI646970B (zh) * 2012-12-17 2019-01-11 大塚製藥股份有限公司 活化輔助ｔ細胞的方法
PT2945647T (pt) 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
RU2014102939A (ru) 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Вакцинная композиция для чрескожного введения
JP6512568B2 (ja) 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用ｗｔ１ペプチド癌ワクチン組成物
US10206985B2 (en) 2013-02-05 2019-02-19 Nitto Denko Corporation WT1 peptide cancer vaccine composition for mucosal administration
CA2840959A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition
US20140220058A1 (en) 2013-02-05 2014-08-07 Nitto Denko Corporation Vaccine composition for transdermal or mucosal administration
EP2762156A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Tape preparation of WT1 peptide cancer vaccine for transdermal administration
KR20140099828A (ko) 2013-02-05 2014-08-13 닛토덴코 가부시키가이샤 점막 투여용 백신 조성물
JP6512567B2 (ja) 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用ｗｔ１ペプチド癌ワクチン組成物
JP6671956B2 (ja) * 2013-03-29 2020-03-25 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
RU2668560C2 (ru) * 2013-03-29 2018-10-02 Сумитомо Дайниппон Фарма Ко., Лтд. Конъюгированная вакцина на основе пептида антигена wt1
EP3231438B1 (en) 2014-12-11 2020-06-17 International Institute of Cancer Immunology, Inc. Wt1 immunotherapy for intraocular angiogenic disease
EP3458095A4 (en) 2016-05-18 2019-11-27 Albert Einstein College of Medicine PD-L1 POLYPEPTIDE VARIANTS, T-LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES AND METHODS OF USING SAME
CN109475628A (zh) 2016-05-18 2019-03-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
EP3558339B1 (en) 2016-12-22 2024-01-24 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
IL309479A (en) 2017-03-15 2024-02-01 Cue Biopharma Inc Methods for modulating an immune response
US20200368338A1 (en) * 2017-12-27 2020-11-26 Sumitomo Dainippon Pharma Co., Ltd. Conjugate of wt1-derived peptides and composition comprising the same
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
CA3169949A1 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
KR20230009426A (ko) * 2020-05-12 2023-01-17 스미토모 파마 가부시키가이샤 암을 처치하기 위한 의약 조성물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575374A (en) * 1983-02-16 1986-03-11 Anis Aziz Y Flexible anterior chamber lens
US5763209A (en) * 1988-09-26 1998-06-09 Arch Development Corporation Methods and materials relating to the functional domains of DNA binding proteins
US5584304A (en) * 1993-11-18 1996-12-17 Allergan, Inc. Method of inserting an IOL using a forceps inside a folding tube
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5984962A (en) * 1996-01-22 1999-11-16 Quantum Vision, Inc. Adjustable intraocular lens
US6207375B1 (en) * 1996-12-11 2001-03-27 Mayo Foundation For Medical Educational & Research TGF-β inducible early factor-1 (TIEF-1) and a method to detect breast cancer
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US20030072767A1 (en) 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) * 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) * 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) * 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) * 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) * 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
CA2349442C (en) * 1998-09-30 2012-12-04 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
YU72901A (sh) * 1999-04-02 2004-07-15 Corixa Corporation Preparati za primenu u terapiji i dijagnozi raka pluća
WO2001025273A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US20030082194A1 (en) * 2000-02-22 2003-05-01 Alexander Gaiger Compositions and methods for diagnosis and therapy of malignant mesothelioma
AU2001247220A1 (en) * 2000-02-22 2001-09-03 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
TWI318630B (en) * 2001-03-22 2009-12-21 Int Inst Cancer Immunology Inc Wt1 modified peptide
IL145015A0 (en) * 2001-08-21 2002-06-30 Nun Yehoshua Ben Accommodating lens
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
AU2003242305A1 (en) 2002-06-12 2003-12-31 Chugai Seiyaku Kabushiki Kaisha Hla-a24-restricted cancer antigen peptide
CA2487489C (en) 2002-06-14 2010-11-23 Merck & Co., Inc. Mitotic kinesin inhibitors
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
WO2004063217A1 (ja) 2003-01-15 2004-07-29 Chugai Seiyaku Kabushiki Kaisha 二量体化ペプチド
US7976520B2 (en) * 2004-01-12 2011-07-12 Nulens Ltd. Eye wall anchored fixtures
DE602005020121D1 (de) 2004-03-31 2010-05-06 Int Inst Cancer Immunology Inc Aus wt1 stammende krebsantigenpeptide
JP2006045287A (ja) 2004-08-02 2006-02-16 Inax Corp 弾性接着剤及びタイル張り壁面
JP4719876B2 (ja) 2005-04-04 2011-07-06 国立大学法人愛媛大学 Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring

Also Published As

Publication number Publication date
JPWO2008081701A1 (ja) 2010-04-30
EP2980219A1 (en) 2016-02-03
NZ577443A (en) 2011-12-22
CN102335439A (zh) 2012-02-01
EP2341142B1 (en) 2014-11-26
TW201345544A (zh) 2013-11-16
NZ601175A (en) 2012-12-21
AU2007340679B2 (en) 2013-09-12
US20140134200A1 (en) 2014-05-15
CA2886620A1 (en) 2008-07-10
TW201630620A (zh) 2016-09-01
CN102302788A (zh) 2012-01-04
CN102335439B (zh) 2015-04-22
KR20090102772A (ko) 2009-09-30
IL215334A0 (en) 2011-11-30
IL215332A0 (en) 2011-11-30
TWI599367B (zh) 2017-09-21
US9272026B2 (en) 2016-03-01
US8653038B2 (en) 2014-02-18
CA2886621A1 (en) 2008-07-10
KR101525261B1 (ko) 2015-06-02
CN101573448B (zh) 2012-07-11
ES2554775T3 (es) 2015-12-23
DK2479275T3 (en) 2015-12-14
MX2009007008A (es) 2009-07-10
JP5484734B2 (ja) 2014-05-07
TW200835513A (en) 2008-09-01
CA2886619A1 (en) 2008-07-10
EP2980219B1 (en) 2018-11-14
UA103154C2 (uk) 2013-09-25
EP2479275A1 (en) 2012-07-25
HK1221252A1 (zh) 2017-05-26
EP3026115B1 (en) 2017-05-17
AR064555A1 (es) 2009-04-08
ZA200903633B (en) 2010-02-24
CN102302788B (zh) 2016-06-15
NZ592510A (en) 2012-11-30
RU2009128979A (ru) 2011-02-10
SG177222A1 (en) 2012-01-30
EP2479276A1 (en) 2012-07-25
CN102295682A (zh) 2011-12-28
EP2098595A4 (en) 2010-03-17
CY1116011T1 (el) 2017-01-25
TWI417103B (zh) 2013-12-01
WO2008081701A1 (ja) 2008-07-10
ES2556831T3 (es) 2016-01-20
IL215333A0 (en) 2011-11-30
EP2479275B1 (en) 2015-10-28
IL199052A0 (en) 2010-03-28
SI2341142T1 (sl) 2015-03-31
AU2007340679A1 (en) 2008-07-10
US20180064795A1 (en) 2018-03-08
PH12014500902B1 (en) 2016-01-11
CN102659924A (zh) 2012-09-12
BRPI0720988A2 (pt) 2014-03-18
EP2341142B8 (en) 2015-01-14
EP2479276B1 (en) 2015-12-09
CA2670658A1 (en) 2008-07-10
EP2341142A3 (en) 2011-09-07
HK1173187A1 (zh) 2013-05-10
DK2479276T3 (en) 2015-12-21
CA2886622A1 (en) 2008-07-10
ES2526425T3 (es) 2015-01-12
US20160199472A1 (en) 2016-07-14
CN101573448A (zh) 2009-11-04
DK2341142T3 (en) 2014-12-08
RU2481398C2 (ru) 2013-05-10
ES2629578T3 (es) 2017-08-11
HK1159686A1 (en) 2012-08-03
EP2341142A2 (en) 2011-07-06
PH12014500902A1 (en) 2016-01-11
MY161664A (en) 2017-04-28
PL2341142T3 (pl) 2015-04-30
EP2098595A1 (en) 2009-09-09
TWI554280B (zh) 2016-10-21
CN102659924B (zh) 2015-11-25
US20110098233A1 (en) 2011-04-28
NZ592509A (en) 2012-11-30
NO20092774L (no) 2009-07-27
EP3026115A1 (en) 2016-06-01

Similar Documents

Publication Publication Date Title
PL2341142T3 (pl) Ograniczony za pomocą peptydu WT1 HLLA-A 1101i zawierające je kompozycje
IL232409A0 (en) 3033*a-hla- reduced 1wt peptide and pharmaceutical compound containing it
IL275854A (en) Pharmaceutical composition and its administration
HUS1700016I1 (hu) Liraglutidot és degludeket tartalmazó stabil gyógyszerészeti készítmények
IL242883B (en) Aryl-amino and heteroaryl-amino converted deoxazolines and pharmaceutical preparations containing them
EP2056835A4 (en) PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
IL194546A0 (en) Arylaminopyridine derivatives and pharmaceutical compositions containing them
IL194429A0 (en) Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
HK1141312A1 (en) Cdca1 peptide and pharmaceutical agent comprising the same cdca1
PL2154966T3 (pl) Benzoimidazole i ich kompozycje farmaceutyczne
EP1890677A4 (en) PHARMACEUTICAL COMPOSITIONS AND THEIR USE
IL193211A (en) Derivatives of Indzol-Troaril and pharmaceutical preparations containing them
GB0610090D0 (en) Particulate drug compositions and their uses
GB0604187D0 (en) Peptide and uses thereof
GB0614365D0 (en) Pharmaceutical compositions and their use
IL192824A (en) Peptide compounds, pharmaceuticals containing them and their use
EP1937292A4 (en) LOPAP-BASED PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
IL178937A0 (en) Pharmaceutical and cosmetic compositions
GB0724523D0 (en) Pharmaceutical compositions comprising clotrimazole or analogs thereof and their use
PL378824A1 (pl) Peptyd i jego zastosowanie